Shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $5.42.

CATB has been the subject of a number of recent analyst reports. Cowen and Company restated a “market perform” rating and set a $2.00 price objective on shares of Catabasis Pharmaceuticals in a research note on Friday, October 6th. Oppenheimer Holdings, Inc. lowered their price objective on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a research note on Tuesday, August 15th. HC Wainwright raised their price objective on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Monday, August 14th. CIBC restated an “outperform” rating and set a $7.00 price objective (up previously from $4.00) on shares of Catabasis Pharmaceuticals in a research note on Thursday, October 5th. Finally, Citigroup Inc. restated a “hold” rating and set a $1.50 price objective on shares of Catabasis Pharmaceuticals in a research note on Friday, September 29th.

Shares of Catabasis Pharmaceuticals (CATB) traded down 2.53% during trading on Wednesday, hitting $2.31. The stock had a trading volume of 265,534 shares. The company’s market cap is $51.93 million. The stock’s 50-day moving average price is $2.13 and its 200-day moving average price is $2.13. Catabasis Pharmaceuticals has a one year low of $1.08 and a one year high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.08. On average, equities research analysts forecast that Catabasis Pharmaceuticals will post ($1.39) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Oppenheimer & Co. Inc. grew its stake in Catabasis Pharmaceuticals by 33.3% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 30,000 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Catabasis Pharmaceuticals during the 1st quarter valued at approximately $106,000. Finally, Virtu KCG Holdings LLC acquired a new stake in Catabasis Pharmaceuticals during the 2nd quarter valued at approximately $271,000. Hedge funds and other institutional investors own 32.90% of the company’s stock.

WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/21/catabasis-pharmaceuticals-inc-catb-receives-5-42-average-target-price-from-brokerages.html.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Stock Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.